Home > Rheumatology > ACR 2020 > Spotlight on Rheumatoid Arthritis > Rheumatoid arthritis and interstitial lung disease: a deadly combination

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By
Prof. Joan Bathon, Columbia University, USA
Conference
ACR 2020
Rheumatoid arthritis-associated interstitial lung disease is difficult to control. The combination of DMARDs with antifibrotics might improve the prognosis for this difficult-to-treat patient population. “Approximately 25% of patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) die in the first year after diagnosis, and only around 20% are alive 8 years after the initial diagnosis,” Prof. Joan Bathon (Columbia University, USA) said [1]. Thus, mortality is considerably higher compared with RA patients without ILD. In total, the prevalence of RA-associated ILD is estimated between 8% and 15%, a 9-fold risk elevation compared to the general population. How RA medications influence the risk of developing ILD is a matter of debate. ”It seems unlikely that methotrexate is worsening ILD, but I don´t know whether we will ever get to the root of this problem because RA itself is causing ILD and sorting this out from the treatmen...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on